# Corcept Therapeutics (CORT) — Earnings

CORT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cort/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.36 |
| EPS estimate | $0.02 |
| EPS surprise | +1381.48% |
| Revenue surprise | +15.83% |
| Revenue | $256.1M |
| Revenue estimate | $221.1M |
| Reported | Jul 29, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1088856/000162828026050613/cort-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/370558c8-990a-402a-780e-d3f3794c4e72.html) |

Corcept Therapeutics reported Q2 2026 results on July 29, 2026. Earnings per share were $0.36, against an estimate of $0.02, a surprise of 1381.48%. Revenue was $256.1 million, beating the $221.1 million consensus by 15.83% and setting a high for the table. Compared with Q2 2025, EPS rose about 24% from $0.29 and revenue rose about 32% from $194.4 million.

The quarter followed a loss. In Q1 2026, Corcept lost $0.30 per share against an expected loss of $0.11, the only loss in the table. Revenue has grown every year shown, from $401.9 million in 2022 to $761.3 million in 2025. Annual EPS has been less steady: $0.88 in 2022, $0.95 in 2023, $1.24 in 2024 and $0.82 in 2025. The first half of 2026 adds up to $0.06 per share, against $0.46 a year earlier. Over the last 20 quarters, Corcept beat the EPS estimate 13 times and missed 7 times.

Corcept reported Q3 between October 30 and November 4 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether the return to profit in Q2 holds.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 29, 2026 | $0.02 | $0.36 | 1381.48% | $221.1M | $256.1M |
| Q1 2026 | Apr 30, 2026 | −$0.11 | −$0.30 | -176.50% | $185.8M | $164.9M |
| Q4 2025 | Feb 24, 2026 | $0.33 | $0.20 | -39.30% | $256.9M | $202.1M |
| Q3 2025 | Nov 4, 2025 | $0.16 | $0.16 | -2.26% | $223.2M | $207.6M |
| Q2 2025 | Jul 31, 2025 | $0.19 | $0.29 | 54.67% | $199.4M | $194.4M |
| Q1 2025 | May 5, 2025 | $0.14 | $0.17 | 19.30% | $177.9M | $157.2M |
| Q4 2024 | Feb 26, 2025 | $0.43 | $0.26 | -39.01% | $198.7M | $181.9M |
| Q3 2024 | Oct 30, 2024 | $0.28 | $0.41 | 45.44% | $172.0M | $182.5M |
| Q2 2024 | Jul 29, 2024 | $0.23 | $0.32 | 39.13% | $155.1M | $163.8M |
| Q1 2024 | May 1, 2024 | $0.22 | $0.25 | 13.64% | $141.2M | $146.8M |
| Q4 2023 | Feb 15, 2024 | $0.26 | $0.28 | 8.49% | $129.3M | $135.4M |
| Q3 2023 | Nov 1, 2023 | $0.22 | $0.28 | 28.26% | $119.7M | $123.6M |
| Q2 2023 | Aug 2, 2023 | $0.15 | $0.25 | 66.67% | $109.6M | $117.7M |
| Q1 2023 | May 3, 2023 | $0.20 | $0.14 | -29.51% | $104.9M | $105.7M |
| Q4 2022 | Feb 28, 2023 | $0.24 | $0.14 | -41.59% | $105.1M | $103.1M |
| Q3 2022 | Nov 3, 2022 | $0.23 | $0.30 | 28.21% | $107.6M | $101.7M |
| Q2 2022 | Aug 3, 2022 | $0.24 | $0.24 | 1.39% | $101.0M | $103.4M |
| Q1 2022 | May 5, 2022 | $0.23 | $0.20 | -13.68% | $98.9M | $93.7M |
| Q4 2021 | Feb 15, 2022 | $0.23 | $0.26 | 15.56% | $100.6M | $98.8M |
| Q3 2021 | Nov 3, 2021 | $0.22 | $0.24 | 11.63% | $97.2M | $96.1M |

## Frequently Asked Questions

### When did Corcept Therapeutics (CORT) last report earnings?

Corcept Therapeutics last reported on Jul 29, 2026, covering fiscal Q2 2026.

### Did CORT beat earnings estimates?

Yes. Corcept Therapeutics reported EPS of $0.36 for Q2 2026 against a $0.02 estimate — a 1381.48% beat.

### How much revenue did CORT report last quarter?

Corcept Therapeutics reported $256.1M in revenue for Q2 2026, against a consensus estimate of $221.1M.

## Similar Stocks

- [ANVS](https://www.lighthorse.io/tickers/anvs) — Annovis Bio, Inc. Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).